Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03489304 · ClinicalTrials.gov registry record · Phase 2
Zaleplon in HIV Patients With Depression
A Phase 2 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT03489304: Completed Phase 2 study, sponsored by University of Pennsylvania.
NCT03489304 is a Phase 2 study that has completed, run by University of Pennsylvania. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03489304, a Phase 2 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
In HIV positive patients with sleep onset insomnia and receiving pharmacologic treatment for comorbid depression, the proposed study aims to evaluate the impact of zaleplon on sleep measures determined by insomnia severity index (ISI) and Epworth sleepiness scale (ESS).
Interventions
- DRUG Zaleplon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2014-04-03 |
| Est. Completion | 2015-02-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03489304
The ClinicalTrials.gov registry entry for NCT03489304 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zaleplon is the first listed.
NCT03489304 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03489304 about?
NCT03489304 is a clinical study titled "Zaleplon in HIV Patients With Depression". In HIV positive patients with sleep onset insomnia and receiving pharmacologic treatment for comorbid depression, the proposed study aims to evaluate the impact of zaleplon on sleep measures determined by insomnia severity index (ISI) and Epworth sleepiness scale (ESS).
What is the current status of trial NCT03489304?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2014-04-03. Estimated completion is 2015-02-04.
What interventions are being tested in trial NCT03489304?
The interventions under investigation include: Zaleplon (DRUG).
Who is sponsoring clinical trial NCT03489304?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.